Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDU2Y0
|
|||
| Drug Name |
Vupanorsen
|
|||
| Synonyms |
IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Hypertriglyceridemia [ICD-11: 5C80.1; ICD-10: E78.1, E78.3; ICD-9: 272.1, 427] | Phase 2 | [1] | |
| Non-alcoholic fatty liver disease [ICD-11: DB92; ICD-10: K76.0; ICD-9: 571.8] | Phase 2 | [1] | ||
| Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 2 | [1] | ||
| Company |
Akcea Therapeutics; Ionis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ANGPTL3 messenger RNA (ANGPTL3 mRNA) | Target Info | Inhibitor | [2] |
| Pathway Interaction Database | Integrins in angiogenesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03371355) Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.